Cellectar Biosciences Inc
CLRB4.878USD
+0.158+3.34%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
7.49MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cellectar Biosciences Inc Unternehmen
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Unternehmensinformationen
BörsenkürzelCLRB
Name des UnternehmensCellectar Biosciences Inc
IPO-datumMay 20, 2005
CEOMr. James V. Caruso
Anzahl der mitarbeiter11
WertpapierartOrdinary Share
GeschäftsjahresendeMay 20
Addresse100 Campus Drive
StadtFLORHAM PARK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl07932
Telefon16084418120
Websitehttps://www.cellectar.com/
BörsenkürzelCLRB
IPO-datumMay 20, 2005
CEOMr. James V. Caruso
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 26
Aktualisiert: Sat, Jul 26
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
3.70%
Individual Investor
1.91%
Investment Advisor/Hedge Fund
1.28%
Hedge Fund
1.21%
Corporation
0.36%
Research Firm
0.23%
Venture Capital
0.13%
Bank and Trust
0.03%
Other
91.15%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
84
202.41K
7.72%
-340.14K
2025Q1
86
199.12K
11.22%
-346.61K
2024Q4
85
5.89M
13.20%
-10.24M
2024Q3
82
15.21M
37.53%
+860.01K
2024Q2
87
12.77M
37.42%
+1.31M
2024Q1
84
10.31M
32.95%
-1.69M
2023Q4
71
9.17M
43.97%
+2.46M
2023Q3
74
3.14M
32.62%
+389.97K
2023Q2
83
3.71M
38.83%
+394.07K
2023Q1
91
3.81M
40.21%
+165.83K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
57.40K
2.14%
-172.00
-0.30%
Mar 31, 2025
UBS Financial Services, Inc.
29.84K
1.11%
+17.42K
+140.12%
Mar 31, 2025
Adar1 Capital Management LLC
18.19K
0.68%
+16.85K
+1256.45%
Apr 17, 2025
Lytton (Laurence W)
16.78K
0.63%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
14.78K
0.55%
+3.08K
+26.38%
Mar 31, 2025
Longcor (Jarrod)
2.77K
0.18%
+1.00K
+56.47%
Apr 17, 2025
Squarepoint Capital LLP
12.36K
0.46%
-4.98K
-28.71%
Mar 31, 2025
Caruso (James V)
1.64K
0.11%
--
--
Apr 17, 2025
Citadel Advisors LLC
11.44K
0.43%
+11.44K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Datum
Art
Verhältnis
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
